When Your Eyes Pay the Price for Diabetes
Your retina is like the film in a camera — it captures everything you see. But in people with diabetes, leaking blood vessels can cause fluid to build up in the center of the retina. This condition, called diabetic macular edema (DME), blurs central vision and can make it hard to read, drive, or recognize faces.
DME affects millions of people with diabetes worldwide. And while treatments exist, many patients find that their current medication stops working as well over time. So what happens then?
The Drug That Was Already Doing Well
Doctors have used anti-VEGF injections for years to treat DME. These drugs work by blocking a protein that causes leaky blood vessels in the eye. Think of VEGF as a faulty faucet — anti-VEGF drugs turn the tap down, reducing the flood of fluid pressing on your retina.
Aflibercept has been one of the most-used options. But a newer drug, brolucizumab, has been showing strong results. The question researchers wanted to answer: does it still work if you've already been treated with other anti-VEGF drugs?
The Study Behind the Question
The KINGFISHER trial enrolled 517 people with DME. About 71% had never received anti-VEGF treatment before, while 29% had already tried other injections. Both groups were randomly assigned to either brolucizumab 6 mg or aflibercept 2 mg. Researchers tracked vision scores, retinal fluid levels, and safety over 52 weeks.
For people who had already been treated before, brolucizumab produced an average gain of 11.0 letters on a vision chart. Aflibercept led to an 8.6-letter gain in the same group. That's a meaningful difference for people who had already been through treatment.
More strikingly, brolucizumab reduced the thickness of the central retina by about 255 micrometers in previously treated patients — compared to 190 micrometers with aflibercept. Thinner retina means less fluid pressing on your vision.
A Detail Worth Knowing
But there's a catch.
In people who had never been treated before, both drugs performed almost equally well on vision scores. The stronger advantage for brolucizumab appeared mostly in the prior-treatment group.
What the Bigger Picture Looks Like
Eye specialists see this as meaningful because many people with DME eventually stop responding as well to their first drug. Having data that shows brolucizumab can still produce gains in that group gives doctors another option rather than simply switching to a similar medication.
Inflammation in the eye (called intraocular inflammation) is a known risk with brolucizumab. In this study, the rates were low — around 4% in both treatment groups — but this is something doctors watch closely.
If you have DME and your current eye injections aren't working as well as they used to, this research suggests brolucizumab may still offer real improvement. It's not a one-time fix — it still requires regular clinic visits and injections. Talk to your ophthalmologist about whether switching is right for your situation.
This treatment is available, but the decision to switch medications should be made with your eye doctor based on your specific history.
The Fine Print
This was a post hoc analysis, meaning the groups were compared after the original trial ended rather than being pre-planned. That makes the findings useful but not definitive. The study also wasn't designed to directly compare outcomes between the two subgroups, so some caution is warranted when interpreting the differences.
Where Things Go From Here
Larger trials designed specifically to test brolucizumab in previously treated DME patients would help confirm these findings. For now, the KINGFISHER data adds to a growing picture that brolucizumab holds its own — and may even outperform — in people who have already been through other anti-VEGF options.
